For the quarter ending 2026-03-31, JBIO had -$14,073K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 55,110 | -25,175 | -70,303 |
| Change in fair value of convertible notes payable | - | 0 | 21,584 |
| Stock-based compensation | -3,208 | 4,295 | 6,318 |
| Non-cash lease expense | -31 | -17 | 74 |
| Accretion/amortization on investments | 319 | 174 | - |
| Depreciation expense | -8 | 12 | 5 |
| Prepaid expenses and other current assets | -7,215 | 413 | 1,358 |
| Other assets | - | - | -88 |
| Accounts payable | 2,268 | -4,878 | 4,938 |
| Accrued expenses and other current liabilities | -1,668 | 4,578 | 2,862 |
| Related party accrued expenses and other current liabilities | -719 | -332 | -3,124 |
| Operating lease liabilities | -97 | 68 | - |
| Net cash used in operating activities | 36,959 | -22,124 | -38,916 |
| Purchases of investments | -74,694 | 148,592 | - |
| Payment of security deposit | - | 59 | - |
| Purchases of property and equipment | - | 57 | 136 |
| Proceeds from sales/maturities of investments | 65,428 | - | - |
| Net cash used in investing activities | 140,374 | -148,708 | -136 |
| Payments of debt issuance costs-December PIPEFinancing | 809 | - | - |
| Proceeds from the pre-closing financing, net of 14,548 of offering costs | - | 0 | 190,452 |
| Payments of debt issuance costs-October PIPEFinancing | 31 | - | - |
| Cash acquired in connection with the reverse recapitalization | - | 0 | 156 |
| Proceeds from stock option exercises | 45 | - | - |
| Net cash provided by financing activities | -191,403 | 0 | 190,608 |
| Effect on exchange rates on cash and cash equivalents | -3 | -4 | - |
| Net decrease in cash and cash equivalents | -14,073 | -170,836 | 151,556 |
| Cash and cash equivalents at beginning of period | 50,106 | 69,386 | - |
| Cash and cash equivalents at end of period | 55,085 | 50,106 | - |
Jade Biosciences, Inc. (JBIO)
Jade Biosciences, Inc. (JBIO)